DIAGNOS (CVE:ADK) Sets New 12-Month High – Should You Buy?

DIAGNOS Inc. (CVE:ADK)’s share price reached a new 52-week high on Wednesday . The company traded as high as C$0.42 and last traded at C$0.40, with a volume of 183300 shares trading hands. The stock had previously closed at C$0.39.

DIAGNOS Stock Performance

The company has a market capitalization of C$46.72 million, a price-to-earnings ratio of -9.70 and a beta of -0.14. The stock’s 50 day moving average price is C$0.28 and its 200 day moving average price is C$0.26. The company has a current ratio of 1.49, a quick ratio of 0.68 and a debt-to-equity ratio of 204.05.

Insiders Place Their Bets

In related news, Director Robert Dunn purchased 200,000 shares of the firm’s stock in a transaction on Wednesday, July 29th. The stock was purchased at an average cost of C$0.30 per share, for a total transaction of C$60,000.00. Following the completion of the purchase, the director directly owned 2,117,778 shares in the company, valued at C$635,333.40. This trade represents a 10.43% increase in their ownership of the stock. Insiders purchased 328,571 shares of company stock valued at $96,000 in the last ninety days. 16.81% of the stock is owned by company insiders.

About DIAGNOS

DIAGNOS Inc provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence.